Viavi Solutions stock analysis: revenue up 52.5% and a 60.9% gross margin, but a net loss and 36x EV/EBITDA keep VIAV at Hold.
@2026 – All Right Reserved.
Tag:
Hold
-
-
BiotechnologyUS Stocks
Madrigal’s Revenue Is Up 71% as Rezdiffra Ramps – the Stock Is Already Near Its Highs
Madrigal Pharmaceuticals stock analysis: 71% revenue growth meets a rich 24x price-to-book near two-year highs. Model signal: Hold.
-
Insmed Incorporated stock analysis: revenue up 296.1% with a 90/100 growth score, offset by a -76.9% net margin and a Hold signal from our model.
-
GitLab stock analysis: GTLB posts the strongest Growth score in coverage at 85/100, but the model still rates the stock a Hold overall.
-
Intel stock analysis: INTC has rallied off its two-year low on 25.4% revenue growth, but a weak Opportunity score keeps the model at Hold.
-
Snowflake stock analysis: SNOW hits a two-year high on 33.5% revenue growth, but an 11/100 Opportunity score flags a stretched valuation.
-
Atlassian Corporation stock analysis: 27.6% revenue growth and $1.7B free cash flow, but GAAP losses and a 108x EV/EBITDA keep the model at Hold.